Coronary Flow Reserve Changes After Semaglutide Treatment

The goal of this observational study is to learn about the effects of semaglutide to coronary artery flow in diabetic and non-diabetic patients. The main question it aims to answer is:

Does semaglutide enhance coronary artery flow in diabetic and non-diabetic patients?

Participants already planned taking semaglutide by an endocrine specialist as their treatment was assessed with CFR before and 3 months after.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

The Study Focused on the Vascular Effects of Semaglutide in Both Diabetic and Non-diabetic Patients Body Weight Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Obesity &Amp; Overweight Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

28 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Medicana International Istanbul Hospital

Istanbul, 34520, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients who were planned to start semaglutide.

Exclusion criteria

Ischemic heart disease
Previous stent implantation or coronary bypass
Heart failure
Cardiomyopathies
Inflammatory diseases
Autoimmune rheumatic disease
Chronic liver and renal insufficiency

Treatment and study plan

Primary outcomes

Number of patients who had acute coronary syndrome

Time frame: From start of the study to 3 months after

Semaglutide is known for its beneficial effects on coronary vasculature. If a patient had myocardial infarction, this patient can no longer participate in study because the CFR ultimately changes.

Secondary outcomes

Number of patients who can not lose weight

Time frame: From start to 3 months

Semaglutide is not only a diabetic drug but is also known for its weight loss properties. If the patient is unable to lose weight, additional information should be obtained as to why the drug is not working for this specific patient and should be removed from the study.

Sponsors and collaborators

Lead sponsor

Ekrem Bilal Karaayvaz

Other

Collaborators

MEDICANA

Registry information

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Sep 24, 2025
Registry last updated: Sep 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting